西雅图遗传学公司的罕见癌症药物顺利通过加速批准。 - Suppr

Suppr

超能文献

Seattle Genetics rare cancer drug sails through accelerated approval.

作者信息

DeFrancesco Laura

出版信息

Nat Biotechnol. 2011 Oct 13;29(10):851-2. doi: 10.1038/nbt1011-851.

DOI:10.1038/nbt1011-851

PMID:21997610

Abstract

摘要

相似文献

Seattle Genetics rare cancer drug sails through accelerated approval.

Nat Biotechnol. 2011 Oct 13;29(10):851-2. doi: 10.1038/nbt1011-851.

Brentuximab vedotin.

Drugs R D. 2011;11(1):85-95. doi: 10.2165/11591070-000000000-00000.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.

FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.

Oncology (Williston Park). 2011 Sep;25(10):904.

Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.

BioDrugs. 2014 Jun;28(3):245-51. doi: 10.1007/s40259-013-0077-7.

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289.

Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.

Br J Haematol. 2014 Jul;166(2):306-8. doi: 10.1111/bjh.12849. Epub 2014 Mar 27.

Role of CD30 targeting in malignant lymphoma.

Curr Treat Options Oncol. 2014 Jun;15(2):210-25. doi: 10.1007/s11864-014-0275-7.

Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.

Drugs Today (Barc). 2012 Apr;48(4):259-70. doi: 10.1358/dot.2012.48.4.1788435.

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.

引用本文的文献

A review on advanced methods in plant gene targeting.

J Genet Eng Biotechnol. 2017 Dec;15(2):317-321. doi: 10.1016/j.jgeb.2017.07.004. Epub 2017 Aug 7.

State of the art in the treatment of Hodgkin lymphoma.

Nat Rev Clin Oncol. 2012 Jun 12;9(8):450-9. doi: 10.1038/nrclinonc.2012.91.

Fresh from the biotech pipeline--2011 [corrected].

Nat Biotechnol. 2012 Feb 8;30(2):128-31. doi: 10.1038/nbt.2111.

本文引用的文献

FDA panel votes to pull Avastin in breast cancer, again.

Nat Biotechnol. 2011 Aug 5;29(8):676. doi: 10.1038/nbt0811-676c.

Pushing the envelope.

Nat Biotechnol. 2011 Aug 5;29(8):669. doi: 10.1038/nbt.1956.

Accelerated approval of oncology products: the food and drug administration experience.

J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21.

Accelerated approval of oncology drugs: can we do better?

J Natl Cancer Inst. 2011 Apr 20;103(8):616-7. doi: 10.1093/jnci/djr104. Epub 2011 Mar 21.

Can cancer clinical trials be fixed?

Nat Biotechnol. 2011 Jan;29(1):13-5. doi: 10.1038/nbt.1746.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验